Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B P Kearney

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Journal of the Canadian Dental Association|January 1, 1970
Federal representation on the CDA Board of GovernorsB P Kearney
Scientific and Educational Bulletin|January 1, 1970
Programmed preventive dentistry in the Canadian Armed ForcesB P Kearney
Neurologic Clinics|October 13, 1999
The penetration of anti-infectives into the central nervous systemB P Kearney, F T Aweeka
Journal of the Canadian Dental Association|November 1, 1972
The Tatamagouche project: an experiment in dental educationB P Kearney, J D McLean
Clinical Pharmacology and Therapeutics|September 26, 2008
Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposureA A Mathias, S West, J Hui, et al.
Clinical Pharmacology and Therapeutics|January 1, 2010
Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activityA A Mathias, P German, B P Murray, et al.
Antimicrobial Agents and Chemotherapy|October 2, 2013
Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenanceR Douglas Bruce, P Winkle, J M Custodio, et al.
Antimicrobial Agents and Chemotherapy|January 28, 2005
Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteersJ A H Droste, C P W G M Verweij-van Wissen, B P Kearney, et al.
Antimicrobial Agents and Chemotherapy|September 15, 2001
Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adultsP Barditch-Crovo, S G Deeks, A Collier, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Journal of the Canadian Dental Association|January 1, 1970
Federal representation on the CDA Board of GovernorsB P Kearney
Scientific and Educational Bulletin|January 1, 1970
Programmed preventive dentistry in the Canadian Armed ForcesB P Kearney
Neurologic Clinics|October 13, 1999
The penetration of anti-infectives into the central nervous systemB P Kearney, F T Aweeka
Journal of the Canadian Dental Association|November 1, 1972
The Tatamagouche project: an experiment in dental educationB P Kearney, J D McLean
Clinical Pharmacology and Therapeutics|September 26, 2008
Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposureA A Mathias, S West, J Hui, et al.
Clinical Pharmacology and Therapeutics|January 1, 2010
Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activityA A Mathias, P German, B P Murray, et al.
Antimicrobial Agents and Chemotherapy|October 2, 2013
Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenanceR Douglas Bruce, P Winkle, J M Custodio, et al.
Antimicrobial Agents and Chemotherapy|January 28, 2005
Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteersJ A H Droste, C P W G M Verweij-van Wissen, B P Kearney, et al.
Antimicrobial Agents and Chemotherapy|September 15, 2001
Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adultsP Barditch-Crovo, S G Deeks, A Collier, et al.
Pageof 1